Insider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells 3,000 Shares of Stock

MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston sold 3,000 shares of the stock in a transaction on Monday, January 27th. The stock was sold at an average price of $4.64, for a total value of $13,920.00. Following the completion of the transaction, the director now owns 141,950 shares of the company’s stock, valued at $658,648. The trade was a 2.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

John Joseph Johnston also recently made the following trade(s):

• On Thursday, December 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The stock was sold at an average price of $4.01, for a total transaction of $12,030.00.

MaxCyte Stock Down 1.7 %

Shares of NASDAQ MXCT opened at $4.51 on Friday. The stock has a market capitalization of $476.76 million, a price-to-earnings ratio of -13.26 and a beta of 1.29. MaxCyte, Inc. has a 52 week low of $3.16 and a 52 week high of $5.29. The firm has a 50-day moving average price of $4.25 and a 200 day moving average price of $4.09.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The company had revenue of $8.16 million during the quarter, compared to the consensus estimate of $7.50 million. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. During the same period last year, the firm earned ($0.11) EPS. Equities research analysts expect that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

Hedge Funds Weigh In On MaxCyte

Several hedge funds and other institutional investors have recently bought and sold shares of MXCT. Intech Investment Management LLC purchased a new position in shares of MaxCyte in the third quarter valued at $51,000. China Universal Asset Management Co. Ltd. grew its stake in MaxCyte by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company’s stock valued at $79,000 after acquiring an additional 7,930 shares during the last quarter. Verition Fund Management LLC grew its stake in MaxCyte by 39.5% in the 3rd quarter. Verition Fund Management LLC now owns 21,335 shares of the company’s stock valued at $83,000 after acquiring an additional 6,045 shares during the last quarter. Creative Planning increased its holdings in MaxCyte by 33.6% during the 3rd quarter. Creative Planning now owns 28,652 shares of the company’s stock valued at $111,000 after acquiring an additional 7,212 shares in the last quarter. Finally, SG Americas Securities LLC raised its position in MaxCyte by 84.5% during the third quarter. SG Americas Securities LLC now owns 37,969 shares of the company’s stock worth $148,000 after acquiring an additional 17,385 shares during the last quarter. 68.81% of the stock is owned by institutional investors and hedge funds.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.